Clinical trials
catalyst calendar across sponsors →Studies where EOLS is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
5 interventional · 1 observational · 5 with posted results
Held by 10 tracked-famous managers (MILLENNIUM MANAGEMENT LLC, Point72 Asset Management, L.P., CITADEL ADVISORS LLC, D. E. Shaw & Co., Inc., RENAISSANCE TECHNOLOGIES LLC, +5 more) · FINRA short interest 8.7 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| Non Interventional Safety Study of NUCEIVA for the Treatment of Moderate-to-Severe Glabellar LinesNCT05481931observationalTreatment Emergent Adverse Events | — | Completed | Drug: prabotulinumtoxinA | Glabellar Frown Lines | 756 | 2026-04-13actual | 2026-06-30 |
| Study to Demonstrate Safety and Duration of Effect of 40 Units of PrabotulinumtoxinA-xvfs to Treat Glabellar LinesNCT05320393results2024-09-04Duration of Effect Described by Kaplan-Meier AnalysisRandomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: PrabotulinumtoxinA-Xvfs, OnabotulinumtoxinA, PrabotulinumtoxinA-Xvfs | Glabellar Frown Lines | 154 | 2023-05-22actual | 2024-09-04 |
| Safety Study of DWP-450 (Botulinum Toxin, Type a) to Treat Glabellar Lines - EV-006NCT02428608results2019-02-05The Safety of Repeat DWP-450 Treatments - Proportion of Subjects With at Least One Adverse Event Over 1 YearOpen-label · Treatment | Phase 2 | Completed | Biological: DWP-450 (Botulinum purified neurotoxin, Type A) | Glabellar Frown Lines | 570 | Oct 2016actual | 2019-04-24 |
| Safety Study of DWP-450 (Botulinum Purified Neurotoxin, Type A) Injection to Treat Glabellar LinesNCT02184988results2019-02-05The Safety of Repeat DWP-450 Treatments - Proportion of Subjects With at Least One Adverse Event Over 1 YearOpen-label · Treatment | Phase 2 | Completed | Biological: Botulinum purified neurotoxin, Type A | Glabellar Frown Lines | 352 | Dec 2015actual | 2019-04-24 |
| A Phase III Study to Demonstrate the Safety and Efficacy of DWP-450 to Treat Glabellar Lines - EV001NCT02334423results2019-02-26Percentage of Participants With a ≥2 Point Improvement in Glabellar Line Scale (GLS) as Independently Assessed by Investigator and and SubjectRandomized · Quadruple-masked · Treatment | Phase 3 | Completed | Biological: Botulinum toxin, Type A · Other: 0.9% sterile, unpreserved saline | Glabellar Frown Lines | 330 | Dec 2015actual | 2019-03-27 |
| A Phase III Study to Demonstrate the Safety and Efficacy of DWP-450 to Treat Glabellar Lines - EV-002NCT02334436results2019-02-27Percentage of Participants With a ≥2 Point Improvement in Glabellar Line Scale (GLS) as Independently Assessed by Investigator and and SubjectRandomized · Quadruple-masked · Treatment | Phase 3 | Completed | Biological: Botulinum toxin, Type A · Other: 0.9% sterile, unpreserved saline | Glabellar Frown Lines | 324 | Sep 2015actual | 2019-03-27 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19